Budget impact of parenteral iron treatment of iron deficiency: Methodological issues raised by using real-life data

European Journal of Health Economics

Volumn 15, Issue 9, 2014, Pages 907-916

  Brock, Elisabeth ^a   Braunhofer, Peter ^b   Troxler, Josef ^c   Schneider, Heinz ^a  

^a HealthEcon Ltd   (Switzerland)

^b Vifor International AG   (Switzerland)

^c Vifor (International) Inc   (Switzerland)

Author keywords

Budget impact analysis; Methodology; Parenteral iron treatment; Real life data; Switzerland

Indexed keywords

FERRIC CARBOXYMALTOSE; IRON SACCHARATE; FERRIC ION; FERRIC OXIDE, SACCHARATED; MALTOSE; SACCHARIC ACID;

ARTICLE; BUDGET; CHRONIC KIDNEY DISEASE; COST CONTROL; DRUG COST; ELECTIVE SURGERY; HEALTH INSURANCE; HEART FAILURE; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY; IRON THERAPY; NEOPLASM; ONCOLOGY; PREGNANCY; PUERPERIUM; REIMBURSEMENT; TREATMENT INDICATION; UTERUS BLEEDING; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; DRUG SUBSTITUTION; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; PUBLIC HEALTH; SWITZERLAND;

ANEMIA, IRON-DEFICIENCY; BUDGETS; COST SAVINGS; DRUG SUBSTITUTION; FEMALE; FERRIC COMPOUNDS; FINANCING, PERSONAL; GLUCARIC ACID; HUMANS; MALTOSE; NATIONAL HEALTH PROGRAMS; SWITZERLAND;

EID: 84919922091     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0533-9     Document Type: Article

References (24)

1. Dunn, L.L., Rahmanto, Y.S., Richardson, D.R.: Iron uptake and metabolism in the new millennium. Trends Cell Biol. 17, 93–100 (2007)
2. Fairbanks, V., Beutler, E: Iron deficiency. In: Beutler, E. (ed.) Williams hematology, 6th edn, pp. 295–304, 447–470. McGraw-Hill, New York (2001)
3. Beard, J.L.: Iron biology in immune function, muscle metabolism and neuronal functioning. J. Nutr. 131(Suppl 2), 568S–579S (2001)
4. Haas, J.D., Brownlie, T.: Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J. Nutr. 131(Suppl 2), 676S–688S (2001)
5. Davies, K.J., Maguire, J.J., Brooks, G.A., Dallman, P.R., Packer, L.: Muscle mitochondrial bioenergetics, oxygen supply, and work capacity during dietary iron deficiency and repletion. Am. J. Physiol. 242(6), E418–E427 (1982)
6. Satija, P., Ondo, W.G.: Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs 22, 497–518 (2008)
7. Schaefer, R.M., Huch, R., Krafft, A., et al.: Eisenbrief—Aktuelle Empfehlungen zur Therapie der Eisenmangelanämie [“The iron letter—an update on the treatment of iron deficiency anaemia”]. Praxis 95, 357–364 (2006)
8. Documed: Arzneimittelkompendium der Schweiz [“Drugs compendium of Switzerland”]. www.kompendium.ch. Accessed 24 July 2013
9. Bundesamt für Gesundheit [“Swiss Ministry of Health”]: Handbuch betreffend die Spezialitätenliste (SL) [“Handbook concerning the Drug Specialties List”]. Version valid from 1st Feb 2008. http://www.bag.admin.ch/themen/krankenversicherung/06492/07568/index.html?lang=de. Accessed 1 Sept 2010
10. Bundesamt für Gesundheit [“Swiss Ministry of Health”]: Antrag auf Kostenübernahme durch die obligatorische Krankenpflegeversicherung (OKP) zur Beurteilung durch die Eidgenössische Kommission für allgemeine Leistungen und Grundsatzfragen (ELGK) [“Application for reimbursement by mandatory health insurance system for assessment by the Federal Commission for general services and questions of principle”]. Version June 2009. http://www.bag.admin.ch/themen/krankenversicherung/00263/00264/04853/index.html?lang=de. Accessed 1st Sept 2010
11. Polyquest AG, Berne, Switzerland: Treatment of iron deficiency—prescriber analysis of parenteral iron products—final analysis [“Eisenmangeltherapie—Verschreiberanalyse parenteraler Eisenprodukte- Endauswertung”] Research conducted January/February 2010. Unpublished data made available to HealthEcon by the manufacturer Vifor. As the specific elements of the Polyquest Prescriber Analysis which were used for the purposes of this analysis are unpublished, electronic supplementary material is provided with the original data relevant to the analysis presented here
12. AplusA Research: Anemia Patient Record Study in Switzerland—a quantitative research for understanding treatment behaviour in anemia through patient records in each of GP, cardiologist, gastroenterologist, onco-haematologist, nephrologist, gynaecologist, pregnancy, gynaecologist HUB, Dec 2009. Unpublished data made available to HealthEcon by the manufacturer Vifor. As the specific elements of the Anemia Patient Record Study in Switzerland which were used for the purposes of this analysis are unpublished, electronic supplementary material is provided with the original data relevant to the analysis presented here
13. IMS Health, Switzerland: National sales data for iron sucrose and ferric carboxymaltose 2007–2009, unpublished data made available to HealthEcon by the manufacturer Vifor
14. Tarmed Suisse: Tarmed Browser 2010. http://www.tarmedsuisse.ch/86.html. Accessed 15th July 2010. And: Santesuisse: Tarmed Tax point values 2010 (unweighted average for administration in physicians’s office in the community). http://www.santesuisse.ch/de/dyn_output.html?content.vcid=6&content.cdid=27398&detail=yes&navid=1695. Accessed 15th July 2010
15. H+ Die Spitäler der Schweiz: Dialyseverträge [“Dialysis contracts”]. http://www.hplus.ch/fileadmin/user_upload/Tarife___Preise/Tarife_und_Preise/Nichtaerztliche_Tarife/Dialyse/Tarifvertrag_gem%C3%A4ss_www-svk_Stand_200808_d.pdf. Accessed 15th July 2010
16. Bundesamt für Gesundheit: Spezialitätenliste (“Specialties List”, list of drugs reimbursed by mandatory health insurance system in Switzerland). http://bag.e-mediat.net/SL2007.Web.External/Default.aspx?webgrab=ignore. Accessed 15th July 2010
17. Bundesamt für Gesundheit: MiGeL (“Mittel- und Gegenstände- Liste”, Official reimbursement tariffs for medical products and devices). http://www.migel.ch/. Accessed 15th July 2010
18. UBS: Currency Calculator. http://www.ubs.com/1/e/index/bcqv/calculator.html. Accessed 9th Jan 2013
19. Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices — budget impact analysis. Value Health 10(5), 336–347 (2007)
20. Mauskopf, J.: Prevalence-based economic evaluation. Value Health 1, 251–259 (1998)
21. Bager, P., Dahlerup, J.F.: The health care costs of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J. Crohn’s Colitis 4(4), 427–430 (2010)
22. Calvet, X., Ruiz, A.M., Dosal, A., et al.: Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One 7(9), e45604 (2012)
23. Fragoulakis, V., Kourlaba, G., Goumenos, D., Konstantoulakis, M., Maniadakis, N.: Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Clinicoecon. Outcomes Res. 4, 127–134 (2012)
24. Wilson, P.D., Hutchings, A., Jeans, A., Macdougall, I.C.: An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J. Med. Econ. 16(1), 108–114 (2013)